Table 1.
Patient Characteristics of the Present Cohort of Cases With T-LGL Lymphoproliferations
| Patient | Age | Gender | % LGL Within CD3 | Circulating LGLs (× 109/L) |
Immunophenotype | Associated Disease | Symptoms | Degree of `Neutropenia | Therapy | Sampling Pre/Post Tx | Impact of Tx on LGL | STAT3 Mutation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LGL1 | 70 | M | 75 | 3.5 | CD8+CD4-CD5-/CD57+ | None | Neutropenia, B-symptoms | Mild | None | Pre | Unknown | No |
| LGL2 | 73 | M | 48 | 4.4 | CD8+CD4-CD57+ | Chronic NK-cell leukemia | Neutropenia, recurrent infections | Mild | MTX | Pre | Unknown | D661Y |
| LGL3 | 67 | M | 55 | 2.0 | CD8+CD4-CD2-/CD57+ | RA | Neutropenia, B symptoms, thrombocytopenia | Mild | Plaquenil | Pre | Unknown | Y640F |
| LGL4 | 72 | M | 72 | - | CD8+CD4- | None | Thrombocytopenia | No | None | Pre | Unknown | Y640F |
| LGL5 | 35 | F | 52 | 3.7 | CD8+CD4-CD57+ | None | Neutropenia | Mild | None | Pre | Unknown | No |
| LGL6 | 74 | F | 41 | 0.8 | CD8+CD4-CD7-/CD57+ | RA, splenomegaly | Neutropenia | Severe | MTX | Pre | Low-level presence | Y640F |
| LGL7 | 58 | M | 6 | 0.6 | CD8+CD4-CD57+ | ITP, MGUS | Asymptomatic (with respect to T-cell clone) | No | None (with respect to T-cell clone) | Pre | Unknown | No |
| LGL8 | 63 | M | 50 | 8.2 | CD8+CD4-CD57+ | M. Waldenström (2005); T-LGL post allo-Tx | Asymptomatic (with respect to T-cell clone) | No | None (with respect to T-cell clone) | Pre | Unknown | No |
| LGL9 | 58 | M | 29 | 6.1 | CD8+CD4-CD57+ | HCL | Asymptomatic (with respect to T-cell clone) | No | None (with respect to T-cell clone) | Pre | Unknown | No |
| LGL10 | 64 | F | 24 | 0.6 | CD8+CD4-CD57+ | Unknown | Neutropenia | Mild | Unknown | Pre | Unknown | Y640F |
| LGL11 | 38 | F | 8 | 0.3 | CD8+CD4-CD5-/CD57+ | None | Neutropenia | Severe | MTX | Pre | Unknown | No |
| LGL12 | 78 | M | 20 | 0.8 | CD8+CD4-CD7-/CD57+ | AML | Asymptomatic (with respect to T-cell clone) | No | None (with respect to T-cell clone) | Pre | Low-level presence | No |
| LGL13 | 76 | F | 52 | 12.0 | CD8+CD4-CD57+ | None | B symptoms | No | None | Pre | Unknown | Y640F |
| LGL14 | 41 | F | 40 | 2.5 | CD8+CD4-CD7-/CD57+ | PRCA | Anemia, B symptoms | No | CSA | Pre | Unknown | No |
| LGL15 | 37 | M | 40 | 1.0 | CD8+CD4-CD5-CD57+ | M. Crohn | Agranulocytosis | Severe | Unknown | Pre | Unknown | Y640F |
| LGL16 | 48 | F | 7 | 0.3 | CD8+CD4-CD57+ | DLBCL (2003, CNS loc 2005) | Neutropenia, anemia | Mild | None (with respect to T-cell clone) | Pre | Unknown | No |
| LGL17 | 27 | M | 44 | 4.2 | CD3+/8+/CD57+ | None | Pancytopenia | Mild | Yes | Post | Yes | No |
| LGL18 | 59 | M | 24 | 2.3 | CD3+/8+/CD57+ | None | Neutropenia, thrombocytopenia | Mild | Yes | Pre | No Tx | No |
| LGL19 | 15 | M | 46 | 1.1 | CD3+/8+/CD57+ | Allo-Tx | AIHA | No | Yes | Pre | Yes | No |
| LGL20 | 51 | F | 41 | 2.2 | CD3+/8+/CD57+ | None | Neutropenia | Mild | Yes | Pre | Yes | No |
| LGL21 | 44 | M | 69 | 5.0 | CD3+/8+/CD57+ | None | None | No | None | Pre | No Tx | D661Y |
| LGL22 | 70 | 6.3 | CD3+/8+/CD57+ | None | None | No | None | Pre | No Tx | Y640F | ||
| LGL23 | 85 | M | 0.6 | CD3+/8+/CD57+ | None | None | No | None | Pre | No Tx | No | |
| LGL24 | 65 | M | 17 | 0.4 | CD3+/8+/CD57+ | None | Neutropenia | Severe | Yes | Pre | Yes | No |
| LGL25 | 35 | M | 29 | 0.8 | CD3+/8+/CD57+ | None | None | No | None | Pre | No Tx | No |
| LGL26 | 32 | M | 23 | 1.8 | CD3+/8+/CD57+ | None | None | No | None | Pre | No Tx | No |
| LGL27 | 73 | M | 40 | 1.6 | CD3+/8+/CD57+ | Smoldering Myeloma | None | Νo | None | Pre | No Tx | No |
aAll T-LGL patients were diagnosed based on the cell morphology/immunophenotype and/or molecular genetics.
AIHA = Autoimmune hemolytic anemia; AML = acute myeloid leukemia; CSA = cyclosporine A; DLBCL = diffuse large B-cell lymphoma; HCL = hairy cell leukemia; Het = heterogeneous; ITP = immune thrombocytopenia; MGUS = monoclonal gammopathy of unknown significance; MTX = methotrexate; PRCA = pure red cell aplasia; RA = rheumatoid arthritis; T-LGL = T cell large granular lymphocyte; Tx = transplantation.